Member Info for Leggster

Oracle

I have just listened again to the Final Results IM, in the 35th minute SP commits to expecting a peer review of the CSR results to be published in a journal during 2024. GLA

My memory agrees with HBD I am expecting the peer review shortly based on the last IM comments, I will be unpleasantly surprised if it's 3-6 months, but we should get some further insight over coming days. GLA

Krone

Thanks for your comments, why though do you think 6 months for the peer review? 6 months for the enhanced toxicity has I agreed been shared but after the last IM I am expecting the peer review far more quickly. I also suspect they and potential partners have had the CSR for sometime now this their bullish commentary. I feel the peer review will be in the relatively near future. Happy though to be corrected if I have missed something. GLA

I hope we will get news before the AGM, whether it's the peer review on 1801 data, 737 news, licensing news on 1801, an 1802 update a T/O but even if there is no news released I want to hear if the BOD are still as upbeat as they have been recently. I still feel the end game is in play. Some of the derampers talk about the board milking salaries, the evidence does not support this eg salary taken as shares, a CEO moving to part time COO. These things point towards deals being struck and an expectation that future developments are expected to be lead by others. This could be a combined 1801 and 1802 deal or TO both deliver exit strategies for the BOD. So irrespective of if we get news in time for the AGM it is coming and IMO will be substantive. GLA

737 news draws ever closer hopefully this won't be the minimums mentioned earlier this year but rather more substantive news, wouldn't it be great if a deal was to be a precursor or a fast follower. GLA

FWIW I would vote against any low ball offer at the levels being discussed but can see that new investors could be tempted.

Yes the length of time is trying but finding undervalued stocks in biotech is IMO one of the areas where you can find alpha return. Loads of risk but lots of return when it goes right for me OXB, SUMM, Silence and SAR have all been good investments and I still believe SAR will be the best. But have also had some failures RENE most recently. So roll on 737 news and a TO/licence we are so close to the end game now that I feel we can almost taste it, the trading pattern this week I think is interesting and I look forward to tomorrow and next week. News is coming and should reset this back to something like real value. GLA

Thanks for sharing the link, good to hear the pitch from Tim

Thanks for the comments on this will be interesting in 737 is priced out of the current share price what news might add. Particularly in the private trial scenario.

Assuming there was news of a substantive nature on 737 does anyone have a view on timing of release? I assume that SEC rules will apply to our Californian pharma and since the deal is with CPF not SAR, that UK RNS timings would apply only in terms of ASAP after release of news. Therefore is it not likely that US news release is likely to be before anything issued by SAR. Does anyone have experience of these types of scenario's?

Looking forward to the next few weeks in particular the 737 news is imminent and could go in any direction but hopefully will add to company value and be a catalyst for a SP boost. I still personally think a deal is being worked through on 1801 and possibly 1802, the extra testing I see as being driven by a potential partner but this could still a be competitive situation with the additional testing being a requirement from a second partner(s) letting them push for a better deal on 1801. High risk end of investing here but with great potential is the stars align and it feels like after a long time we may finally see progress

I assume the large late trade was probably a buy?

Feel news on 737 must be a reality soon hopefully not just the cash and shares. But a real update on progress on moving forward in trial. Though I do wonder if 737 might be bought out in entirety and if that maybe why the long delay on news of trial planning/activity as they have been raising the cash for a full purchase of the molecule. GLA

Completely agree that the tone and excitement in the IM was palpable. Despite the share price I am confidant that this investment is significantly less risky and a strong endgame may occur at any time. GLA

Moving on from HH, will next week see the start of a recovery with buying in advance of peer reviewed data and 737 coming plus a possible deal at some point. At some point we should see some speculative FOMO buying. GLA

It is a time to try and ignore the SP itself and stay focused on future news, two chunky pieces confirmed as coming in this calender year, deal news could be anytime. For those who like to trade good luck but IMO too likely that you could be caught out as news drops and triggers a price correction. I expect the SP to make much more pleasant viewings in the New Year. GLA

Agree Laz on the presentation which I watched last night, this was by far the most upbeat IM I can remember from SAR, the science is looking on the ball, lots of responses to suggest active discussions and interested parties in play. At least two more significant news drops to come in this year in peer review and 737, what's not to like here. GLA

IMO a reasonable RNS a good positive theme throughout, reassurance that safety data was good, pleased to see the positive JAK comment, full safety data to be released this year, the 'further' pointer towards having interested parties, a firm indicator of movement on 1802 and a reminder that 737 news of some sort will come in this calender year. Cash runway is in place. I am satisfied with the content and feel the story is coherent suggesting we are following the published strategy of early development and on licence. Unfortunately I'm in meetings today and cannot join the call so will be interested to see comments later today GLA

I agree with you PCS, unlike many here I believe in SP I think he is doing a good job, he has put the RF scenario behind us, he may or may not be negotiating, he is setting a direction of travel hopefully aligned to partner needs. All business needs a combination of good judgement sprinkled with some good fortune. You can supply the former but not control the second. I am personally still of a mind that SAR continues to become less risky and am still of the opinion that a strong rise can happen with a relatively small news kick start. GLA

Funds raised while available and cash runway secured improves our prospects whether solo or in deal negotiation materially. I will accept the dilution to allow us to continue to develop the science. Personally I expect a rise from high hopefully accelerated by news drops between now and the end of the year. GLA